Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.50 0.76% 66.50 396,194 11:11:37
Bid Price Offer Price High Price Low Price Open Price
65.00 68.00 66.50 66.00 66.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.63 -8.93 -10.09 95.0
Last Trade Time Trade Type Trade Size Trade Price Currency
17:12:49 O 68,116 66.50 GBX

Angle (AGL) Latest News (3)

More Angle News
Angle Takeover Rumours

Angle (AGL) Share Charts

1 Year Angle Chart

1 Year Angle Chart

1 Month Angle Chart

1 Month Angle Chart

Intraday Angle Chart

Intraday Angle Chart

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date Time Title Posts
16/7/201918:11ANGLE PLC - 2019 THREAD - LIQUID BIOPSY COMPANY1,102
28/2/201912:22ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET11,356
28/8/201812:29ANGLE plc (AGL) One to Watch -
02/7/201812:06Still time to look at Angle (AGL)-
14/5/201809:44ANGLE (AGL) Strategic Move-

Add a New Thread

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

Angle Daily Update: Angle Plc is listed in the Support Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 66p.
Angle Plc has a 4 week average price of 54.50p and a 12 week average price of 54.50p.
The 1 year high share price is 85.50p while the 1 year low share price is currently 38p.
There are currently 143,486,522 shares in issue and the average daily traded volume is 249,990 shares. The market capitalisation of Angle Plc is £95,418,537.13.
bones698: Waterloo "just think it's a volume seller " That's quite the statement with no evidence . To wipe millions off the market cap the must be selling 10%of the company shares to create such a drop and also be no buyers of the shares too. Whilst there may well be a seller they tend to sell for a reason and I stick with my theory that a funding is being readied and that is creating the negative impact on the share price . Time will tell but I'm usually on the money as people have seen before . If the share price levels off then you may be right but I see no signs of that happening ATM so stick with my theory for now
jelenko: NY Boy. It all depends on why people invest here. Most of our families have been touched by the horrible illness that AGL are targeting and that may have some influence. Clearly we believe our investments will grow at the same time. I see that STX has had a good run in the lead up to FDA decision. It is likely that AGL will do the same although not guaranteed. STX are involved in the medication side which is different of course to AGL's non invasive liquid biopsy. We don't have side effect issues etc. The constant stream of good results and praise by the present research use users gives me confidence that we will obtain FDA within the next 6-8 months. This is not very long in the scheme of things, we have waited patiently for a number of years already. The prospect of a share price at circa £2.50 in January (if we follow STX uplift profile)is also appealing.
alloa2003: I think the AGL share price is starting to reflect the potential value based on the risk that it may or may not be realised. For example if the potential value was £2 a share (based on profit, pe ratio, etc) and the chance of being successful was deemed 80% then you would expect the price to be much closer to £2. It is a form of arbitration with the share price reflecting the risk/reward factor compared to potential "fair value".
sicilian_kan: If the MBC trial is not, on the existing data (however confident one is) a nailed on certainty, surely the next questions are: 1) What is the best estimate probability of commercial data appearing in the MBC trial? 2) What share price spectrum might arise if the trial demonstrates commercial data? 3) What share price spectrum might arise if the trial does not demonstrate commercial data? Then an investment strategy can be formulated. There is far too little analysis of the actual MBC data that is available. There is also far too little analysis on here of the chance of success and on the share price gains and falls that might occur upon the MBC trial data being released.
alloa2003: There has been a sea change in the AGL share price of late, no highs then sharp reversals on announcements and no drifting on a lack of news. There is strong underlying demand for the shares which leads me to believe things are afoot behind the scenes.
sicilian_kan: At 70p, AGL's fully diluted market cap is £126m. 143,486,522 shares in issue, plus 20,555,806 options etc. = 164,042,328 shares fully diluted. This might see a 75p top before news, but quite frankly, the current share price is way overvalued given the risk involved, the laborious process involved (see youtube video) and the likely revenues from MBC. Given the hype around AGL, I think on good news 100-150p could be hit. On bad MBC results, we are looking at 10p-35p depending on how bad the results are. Results could also be mixed. So short term upside of 50-100%, short term downside potential of 50-80%. Chance of success, say 80-85%? I bear in mind that the ovarian trial was disappointing relative to the earlier study results. With significant downside possibility, I would expect a risk reward ratio of at least 3:1 to make this attractive. Fair price circa 50-55p? For those in at that level, it is definitely worth a hold, but I do not see buying in at the current share price as being in any way attractive.
semper vigilans: As usual a decent bit of research from a large, highly reputable organisation working in the right field, is not really recognised by the market. Whatever one thinks of false starts earlier, at some stage the build up of published, independent research must give the AGL share price a decent, upward shove?
alloa2003: Brexit is not helping sentiment but not the reason for AGL share price weakness. There is literally no interest in the stock at the moment - going to be news driven for some time to come until we see sales and profits. Might drift until it finds support.
alloa2003: I think AGL share price suffers from boredom at times between announcements. Very news driven as profitability is some way off.
alloa2003: Its that time of year - what are your predicitons for the AGL share price in 12 months? I will start at £2 a share :)
Angle share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190716 17:14:13